On Thursday, Merck & Co Inc (NYSE:MRK) announced discontinuing the Phase 3 KeyVibe-008 trial based on an independent Data Monitoring Committee (DMC) recommendation. The trial is evaluating the investigational fixed-dose combination (coformulation) of vibostolimab and Keytruda (pembrolizumab), in combination with chemotherapy, compared to Roche Holdings AG’s (OTC:RHHBY) Tecentriq (atezolizumab) in combination with chemotherapy, for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). Also Read: FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug. At a pre-planned analysis, data showed that the primary endpoint of overall ...